Ken Griffin Pulmonx Corp Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$5.59 - $8.58 $559 - $858	-100 Reduced 25.0%	300 $2,000
Q2 2024 Aug 14, 2024	SELL	$5.77 - $9.82 $4,616 - $7,856	-800 Reduced 66.67%	400 $2,000
Q1 2024 May 15, 2024	SELL	$8.71 - $14.65 $104,520 - $175,800	-12,000 Reduced 90.91%	1,200 $11,000
Q4 2023 Feb 14, 2024	SELL	$7.89 - $13.14 $26,037 - $43,362	-3,300 Reduced 20.0%	13,200 $168,000
Q3 2023 Nov 14, 2023	SELL	$9.88 - $14.0 $70,148 - $99,400	-7,100 Reduced 30.08%	16,500 $170,000
Q2 2023 Aug 14, 2023	SELL	$10.78 - $13.65 $204,820 - $259,350	-19,000 Reduced 44.6%	23,600 $309,000
Q1 2023 May 15, 2023	BUY	$7.49 - $12.54 $308,588 - $516,647	41,200 Added 2942.86%	42,600 $476,000
Q4 2022 Feb 14, 2023	BUY	$4.92 - $17.35 $6,888 - $24,290	1,400 New	1,400 $11,000

124

31M

300

204K

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $241M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.